But at the same time we all know things are always moving - and while Vasepa are alone in its Class of drugs today', a number of Companies is perusing the same goal in trials as R-I did. And I believe there is also Company still working on developing artificial EPA.
Point being - time is always a factor in any sort of business. Competition is always trying to 'Catch Up'.
In other words KM and Amarin have to understand that 'the window' for BO is there 'right now' - because Vascepa is 'alone' in its Class.
Only one of the Big Pharma's will be able to 'keep that advantage' all the way during patent protection period - meaning being so much ahead in all relevant markets WW - that possible later competition wont change much in final revenue.
News 
Market Data 
Discover 
